Vitrian, a leading provider of capital and capacity-building solutions for biomanufacturing, announced the close of a $50 million investment—scalable to $65 million—in AmplifyBio’s Manufacturing Enablement Center (AMEC) in New Albany, Ohio. This investment marks the initial phase of Vitrian’s broader commitment to strengthening biomanufacturing infrastructure in Central Ohio. AmplifyBio, a premier advanced therapy contract research and manufacturing organization (CRO and CDMO), offers comprehensive drug development and manufacturing services.
Located in Central Ohio’s advanced manufacturing hub, near Intel’s $20 billion Ohio One semiconductor facility and Amgen’s $360 million biomanufacturing plant, the 350,000-square-foot AMEC facility houses AmplifyBio’s state-of-the-art process development labs, quality control labs, and GMP manufacturing suites.
“We are thrilled to make our first investment in Ohio and to kick off a strategic partnership with AmplifyBio,” said Scott Nudelman, Co-Founder and Managing Principal at Vitrian. “AmplifyBio’s innovative approach, combined with strong state and local support for biomanufacturing infrastructure and workforce development in Columbus, aligns perfectly with our investment vision.”
J. Kelly Ganjei, CEO of AmplifyBio, added, “We selected Vitrian as a partner due to our shared strategic goals for advancing our manufacturing capabilities. This partnership supports our mission to enable flexible manufacturing and ancillary services in advanced therapy, and we look forward to what we can achieve together.”
About Vitrian
Vitrian is the first fully integrated company dedicated exclusively to providing end-to-end solutions for biomanufacturing and cGMP facilities. Its mission is to foster the next generation of drugs and therapies through facility real estate investment/development, improving the capitalization process, and building capacity for future growth through civic engagement and workforce development. Vitrian is actively engaged in training/capacity building for the entry-level biomanufacturing workforce across its primary markets. Its current engagements span modalities across advanced therapeutics, aseptic fill/finish, synthetic biology, and radiopharma with active projects in 6+ US markets.
About AmplifyBio
AmplifyBio is a contract research and manufacturing organization founded on the principle that all development and scale-up of advanced modality drugs should be done with commercial goals in mind. It was launched out of Battelle in 2021, with an initial offering of industry-leading preclinical toxicology, safety, and pharmacology testing in an agile environment with analytics capabilities that serve the dynamic safety requirements of modern modalities. Since then, AmplifyBio has developed drug characterization and optimization service capabilities and expertise based on the closely held principle that rich characterization, optimization, and data integrity are the keys to reproducibility and scale-up. The company then added GMP manufacturing, completing its concept-to-commercial service offering for the development of advanced therapies.
